David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.

• Section I: Behavioral Neurology1. Cholinesterase Inhibitors for Alzheimer's Disease2. Memantine for Alzheimer's Disease Section II: Epilepsy3. Lorazepam for Generalized Status Epilepticus4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial Section III: Headache6. Sumatriptan for Acute Migraine Section IV: Neuroinfectious Disease7. Steroids for Bell's Palsy8. Steroids for Acute Bacterial Meningitis Section V: Movement Disorders9. Levadopa for Parkinson's Disease10. Deep-Brain Stimulation for Parkinson's Disease Section VI: Multiple Sclerosis11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial Section VII: Neurocritical Care18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial21. Nimodipine for Subarachnoid Hemorrhage Section VIII: Neuromuscular Disease22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome23. IVIG vs. Plasma Exchange for Myasthenia Gravis24. Riluzole for Amyotrophic Lateral Sclerosis Section IX: Neuro-Oncology25. Radiotherapy Plus Temozolomide for Glioblastoma26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma Section X: Neuro-Ophthalmology27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial Section XI: Neuro-Otology28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo Section XII: Sleep29. Modafinil for Narcolepsy30. Continuous Dopamine Agonist for Restless Legs Syndrome Section XIII: Spine Disorders31. Early Surgery for Sciatica32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial Section XIV: Vascular Neurology34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial

David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.

• Section I: Behavioral Neurology1. Cholinesterase Inhibitors for Alzheimer's Disease2. Memantine for Alzheimer's Disease Section II: Epilepsy3. Lorazepam for Generalized Status Epilepticus4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial Section III: Headache6. Sumatriptan for Acute Migraine Section IV: Neuroinfectious Disease7. Steroids for Bell's Palsy8. Steroids for Acute Bacterial Meningitis Section V: Movement Disorders9. Levadopa for Parkinson's Disease10. Deep-Brain Stimulation for Parkinson's Disease Section VI: Multiple Sclerosis11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial Section VII: Neurocritical Care18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial21. Nimodipine for Subarachnoid Hemorrhage Section VIII: Neuromuscular Disease22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome23. IVIG vs. Plasma Exchange for Myasthenia Gravis24. Riluzole for Amyotrophic Lateral Sclerosis Section IX: Neuro-Oncology25. Radiotherapy Plus Temozolomide for Glioblastoma26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma Section X: Neuro-Ophthalmology27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial Section XI: Neuro-Otology28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo Section XII: Sleep29. Modafinil for Narcolepsy30. Continuous Dopamine Agonist for Restless Legs Syndrome Section XIII: Spine Disorders31. Early Surgery for Sciatica32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial Section XIV: Vascular Neurology34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial

David Y. Hwang is the Assistant Professor of Neurology in the Division of Neurocritical Care and Emergency Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.David M. Greer is the The Zimmerman and Spinelli Professor and Vice Chairman of the Department of Neurology at Yale University School of Medicine which is located in New Haven, Connecticut.

• Section I: Behavioral Neurology1. Cholinesterase Inhibitors for Alzheimer's Disease2. Memantine for Alzheimer's Disease Section II: Epilepsy3. Lorazepam for Generalized Status Epilepticus4. Lamotrigine for Partial Epilepsy: Arm A of the SANAD Trial5. Valproate for Generalized and Unclassifiable Epilepsy: Arm B of the SANAD Trial Section III: Headache6. Sumatriptan for Acute Migraine Section IV: Neuroinfectious Disease7. Steroids for Bell's Palsy8. Steroids for Acute Bacterial Meningitis Section V: Movement Disorders9. Levadopa for Parkinson's Disease10. Deep-Brain Stimulation for Parkinson's Disease Section VI: Multiple Sclerosis11. Oral vs. IV Steroids for Acute Relapses of Multiple Sclerosis12. Interferon Beta-1a for a First Demyelinating Event: The CHAMPS Trial13. Glatiramer Acetate for Clinically Isolated Syndrome: The PreCISe Trial14. Natalizumab for Relapsing Multiple Sclerosis: The SENTINEL Trial15. Fingolimod for Relapsing Multiple Sclerosis: The TRANSFORMS Trial16. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part I: The DEFINE Trial17. Oral BG-12 for Relapsing-Remitting Multiple Sclerosis, Part II: The CONFIRM Trial Section VII: Neurocritical Care18. Therapeutic Hypothermia for Cardiac Arrest, Part I: The HACA Trial19. Therapeutic Hypothermia for Cardiac Arrest, Part II: The Australian Trial20. Decompressive Craniectomy for Diffuse Traumatic Brain Injury: The DECRA Trial21. Nimodipine for Subarachnoid Hemorrhage Section VIII: Neuromuscular Disease22. IVIG vs. Plasma Exchange for Guillain-Barre Syndrome23. IVIG vs. Plasma Exchange for Myasthenia Gravis24. Riluzole for Amyotrophic Lateral Sclerosis Section IX: Neuro-Oncology25. Radiotherapy Plus Temozolomide for Glioblastoma26. Methylated MGMT Gene Promoter and Response to Temozolomide for Glioblastoma Section X: Neuro-Ophthalmology27. Steroids for Acute Optic Neuritis: The Optic Neuritis Treatment Trial Section XI: Neuro-Otology28. The Epley Maneuver for Benign Paroxysmal Positional Vertigo Section XII: Sleep29. Modafinil for Narcolepsy30. Continuous Dopamine Agonist for Restless Legs Syndrome Section XIII: Spine Disorders31. Early Surgery for Sciatica32. Surgery for Lumbar Degenerative Spondylolisthesis: The SPORT Trial33. Steroids vs. No Steroids for Acute Spinal Cord Injury: The NASCIS II Trial Section XIV: Vascular Neurology34. IV Thrombolysis 3 Hours After an Acute Ischemic Stroke: The NINDS Trial35. IV Thrombolysis 3 to 4.5 Hours After an Acute Ischemic Stroke: The ECASS III Trial36. Endovascular Therapy for Acute Ischemic Stroke, Part I (Intra-arterial Thrombolysis): The PROACT II Trial37. Endovascular Therapy for Acute Ischemic Stroke, Part II (After IV Thrombolysis): The IMS III Trial38. Endovascular Therapy for Acute Ischemic Stroke, Part III (Using Neuroimaging to Select Patients): The MR RESCUE Trial39. Endovascular Therapy for Acute Ischemic Stroke, Part IV (Clinical Trial Success): The MR CLEAN Trial40. Carotid Endarterectomy for Symptomatic High-Grade Carotid Stenosis: The NASCET Trial, Part I41. Carotid Endarterectomy for Symptomatic Moderate Carotid Stenosis: The NASCET Trial, Part II42. Carotid Endarterectomy for Asymptomatic Carotid Stenosis: The ACAS Trial43. Early Aspirin for Acute Ischemic Stroke: The CAST Trial44. Aspirin vs. Heparin for Acute Ischemic Stroke: The IST Trial45. Dipyridamole and Asprin for Secondary Stroke Prevention: The ESPS-2 Trial46. High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The SPARCL Trial47. Adjusted-Dose Warfarin for Stroke Prevention in High-Risk Atrial Fibrillation Patients: The SPAF III Trial48. Dabigatran for Stroke Prevention in Atrial Fibrillation Patients: The RE-LY Trial49. Apixaban for Stroke Prevention in Atrial Fibrillation Patients: The ARISTOTLE Trial50. Rivaroxaban for Stroke Prevention in Atrial Fibrillation Patients: The ROCKET AF Trial